LYEL — Lyell Immunopharma Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSucker Stock

Annual balance sheet for Lyell Immunopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	PROSPECTUS	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	613	615	640	546	371
Prepaid Expenses
Total Current Assets	618	626	651	555	380
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	124	167	166	142	72.9
Long Term Investments
Other Long Term Assets
Total Assets	908	1,127	938	750	491
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Other Current Liabilities
Total Current Liabilities	49.3	46.7	37	34.5	53.8
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	190	198	104	95.1	108
Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	718	930	833	655	383
Total Liabilities & Shareholders' Equity	908	1,127	938	750	491
Total Common Shares Outstanding